BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 12904083)

  • 1. Conformationally defined retinoic acid analogues. 5. Large-scale synthesis and mammary cancer chemopreventive activity for (2E,4E,6Z,8E)-8-(3',4'-dihydro-1'(2'H)-naphthalen-1'-ylidene)-3,7-dimethyl-2,4,6-octatrienoic acid (9cUAB30).
    Atigadda VR; Vines KK; Grubbs CJ; Hill DL; Beenken SL; Bland KI; Brouillette WJ; Muccio DD
    J Med Chem; 2003 Aug; 46(17):3766-9. PubMed ID: 12904083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methyl substitution of a rexinoid agonist improves potency and reveals site of lipid toxicity.
    Atigadda VR; Xia G; Desphande A; Boerma LJ; Lobo-Ruppert S; Grubbs CJ; Smith CD; Brouillette WJ; Muccio DD
    J Med Chem; 2014 Jun; 57(12):5370-80. PubMed ID: 24801499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conformationally defined retinoic acid analogues. 4. Potential new agents for acute promyelocytic and juvenile myelomonocytic leukemias.
    Muccio DD; Brouillette WJ; Breitman TR; Taimi M; Emanuel PD; Zhang X; Chen G; Sani BP; Venepally P; Reddy L; Alam M; Simpson-Herren L; Hill DL
    J Med Chem; 1998 May; 41(10):1679-87. PubMed ID: 9572893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 9cUAB30, an RXR specific retinoid, and/or tamoxifen in the prevention of methylnitrosourea-induced mammary cancers.
    Grubbs CJ; Hill DL; Bland KI; Beenken SW; Lin TH; Eto I; Atigadda VR; Vines KK; Brouillette WJ; Muccio DD
    Cancer Lett; 2003 Nov; 201(1):17-24. PubMed ID: 14580682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conformationally Defined Rexinoids and Their Efficacy in the Prevention of Mammary Cancers.
    Atigadda VR; Xia G; Deshpande A; Wu L; Kedishvili N; Smith CD; Krontiras H; Bland KI; Grubbs CJ; Brouillette WJ; Muccio DD
    J Med Chem; 2015 Oct; 58(19):7763-74. PubMed ID: 26331194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand.
    Gottardis MM; Bischoff ED; Shirley MA; Wagoner MA; Lamph WW; Heyman RA
    Cancer Res; 1996 Dec; 56(24):5566-70. PubMed ID: 8971154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro metabolic characterization, phenotyping, and kinetic studies of 9cUAB30, a retinoid X receptor-specific retinoid.
    Gorman GS; Coward L; Kerstner-Wood C; Cork L; Kapetanovic IM; Brouillette WJ; Muccio DD
    Drug Metab Dispos; 2007 Jul; 35(7):1157-64. PubMed ID: 17446266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conformationally defined 6-s-trans-retinoic acid analogs. 3. Structure-activity relationships for nuclear receptor binding, transcriptional activity, and cancer chemopreventive activity.
    Muccio DD; Brouillette WJ; Alam M; Vaezi MF; Sani BP; Venepally P; Reddy L; Li E; Norris AW; Simpson-Herren L; Hill DL
    J Med Chem; 1996 Sep; 39(19):3625-35. PubMed ID: 8809153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of papilloma formation by analogues of 7,8-dihydroretinoic acid.
    Shealy YF; Riordan JM; Frye JL; Simpson-Herren L; Sani BP; Hill DL
    J Med Chem; 2003 May; 46(10):1931-9. PubMed ID: 12723955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Murine oncogenicity and pharmacokinetics studies of 9-cis-UAB30, an RXR agonist, for breast cancer chemoprevention.
    Kapetanovic IM; Horn TL; Johnson WD; Cwik MJ; Detrisac CJ; McCormick DL
    Int J Toxicol; 2010; 29(2):157-64. PubMed ID: 20335511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069.
    Wu K; Kim HT; Rodriquez JL; Hilsenbeck SG; Mohsin SK; Xu XC; Lamph WW; Kuhn JG; Green JE; Brown PH
    Cancer Epidemiol Biomarkers Prev; 2002 May; 11(5):467-74. PubMed ID: 12010861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methyl-substituted conformationally constrained rexinoid agonists for the retinoid X receptors demonstrate improved efficacy for cancer therapy and prevention.
    Desphande A; Xia G; Boerma LJ; Vines KK; Atigadda VR; Lobo-Ruppert S; Grubbs CJ; Moeinpour FL; Smith CD; Christov K; Brouillette WJ; Muccio DD
    Bioorg Med Chem; 2014 Jan; 22(1):178-85. PubMed ID: 24359708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma.
    Bischoff ED; Gottardis MM; Moon TE; Heyman RA; Lamph WW
    Cancer Res; 1998 Feb; 58(3):479-84. PubMed ID: 9458093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice.
    Wu K; Zhang Y; Xu XC; Hill J; Celestino J; Kim HT; Mohsin SK; Hilsenbeck SG; Lamph WW; Bissonette R; Brown PH
    Cancer Res; 2002 Nov; 62(22):6376-80. PubMed ID: 12438218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of retinoid treatment of rats on hepatic microsomal metabolism and cytochromes P450. Correlation between retinoic acid receptor/retinoid x receptor selectivity and effects on metabolic enzymes.
    Howell SR; Shirley MA; Ulm EH
    Drug Metab Dispos; 1998 Mar; 26(3):234-9. PubMed ID: 9492386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retinoid X receptor (RXR)-selective retinoid reveals that RXR-alpha is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands.
    Crowe DL; Chandraratna RA
    Breast Cancer Res; 2004; 6(5):R546-55. PubMed ID: 15318936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro assessment of P450 induction potential of novel chemopreventive agents SR13668, 9-cis-UAB30, and pentamethychromanol in primary cultures of human hepatocytes.
    Jackson JP; Kabirov KK; Kapetanovic IM; Lyubimov A
    Chem Biol Interact; 2009 May; 179(2-3):263-72. PubMed ID: 19135037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retinyl ethers as cancer chemopreventive agents. Suppression of mammary cancer.
    Shealy YF; Frye JL; Riordan JM; Hill DL; McPhillips M; Wille JJ; Sani BP; Kalin JR; Eto I; Grubbs CJ
    Anticancer Drug Des; 1997 Jan; 12(1):15-33. PubMed ID: 9051111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of 9-cis-retinoic acid and N-(4-hydroxyphenyl) retinamide alone and in combination in mammary cancer prevention.
    Cope MB; Steele VE; Lubet RA; Eto I; Juliana MM; Hill DL; Grubbs CJ
    Oncol Rep; 2004 Feb; 11(2):465-9. PubMed ID: 14719085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and structure-activity relationships of retinoid X receptor selective diaryl sulfide analogs of retinoic acid.
    Beard RL; Colon DF; Song TK; Davies PJ; Kochhar DM; Chandraratna RA
    J Med Chem; 1996 Aug; 39(18):3556-63. PubMed ID: 8784454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.